• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 67909-49-3 Price $100 / 20mg
    Catalog No.CFN90944Purity>=98%
    Molecular Weight301.4Type of CompoundAlkaloids
    FormulaC19H15N3OPhysical DescriptionYellow powder
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Warszawski Uniwersytet Medyczny (Poland)
  • Nicolaus Copernicus Uniwersity (Poland)
  • Chulalongkorn University (Thailand)
  • Shanghai Institute of Biochemist... (China)
  • University of Lodz (Poland)
  • Florida International University (USA)
  • Donald Danforth Plant Science Ce... (USA)
  • Imperial College London (United Kingdom)
  • Almansora University (Egypt)
  • Universitas islam negeri Jakarta (Indonesia)
  • Molecular Biology Institute of B... (Spain)
  • More...
  • Package
    Featured Products

    Catalog No: CFN92154
    CAS No: 69618-96-8
    Price: $463/5mg
    Platycoside M1

    Catalog No: CFN92267
    CAS No: 917482-67-8
    Price: $468/5mg
    Chlorogenic acid

    Catalog No: CFN99116
    CAS No: 327-97-9
    Price: $30/20mg

    Catalog No: CFN98565
    CAS No: 5373-11-5
    Price: $60/20mg

    Catalog No: CFN99106
    CAS No: 40957-83-3
    Price: $128/20mg
    Biological Activity
    Description: Dehydroevodiamine has anticholinesterase activity and an anti-amnesic effect, it also may be a novel and effective ligand for improvement of beta-amyloid type amnesia. Dehydroevodiamine has antiarrhythmic, and anti-inflammatory properties, the effect of dehydroevodiamine-mediated inhibition of the expression LPS-induced iNOS and COX-2 genes is due to under the suppression of NF-kappaB activation in the transcriptional level.
    Targets: Beta Amyloid | NOS | COX | PGE | NF-kB
    In vitro:
    J Ethnopharmacol. 2014 May 14;153(3):753-62.
    Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes.[Pubmed: 24680993 ]
    Dehydroevodiamine alkaloid (DeHE), a bioactive component of the Chinese herbal medicine Wu-Chu-Yu (Evodiae frutus), exerted antiarrhythmic effect in guinea-pig ventricular myocytes. We further characterize the electromechanical effects of DeHE in the human atrial and ventricular tissues obtained from hearts of patients undergoing corrective cardiac surgery or heart transplantation.
    The transmembrane potentials of human myocardia were recorded with a traditional microelectrode technique while sarcolemmal Na(+) and Ca(2+) currents in single human cardiomyocytes were measured by a whole-cell patch-clamp technique. The intracellular pH (pHi) and Na(+)-H(+) exchanger (NHE) activity were determined using BCECF-fluorescence in human atria. In human atria, DeHE (0.1-0.3 μM) depressed upstroke velocity, amplitude of action potential, and contractile force, both in slow and fast response action potential. Moreover, the similar depressant effects of DeHE were found in human ventricular myocardium. Both in isolated human atrial and ventricular myocytes, DeHE (0.1-1 μM) reversibly, concentration-dependently decreased the Na(+) and Ca(2+)currents. Moreover, DeHE (0.1 and 0.3 μM) suppressed delayed afterdepolarizations and aftercontractions, induced by epinephrine and high [Ca(2+)]o in atria. In human ventricular myocardium, the strophanthidin-induced triggered activities were attenuated by pretreating DeHE (0.3 μM). The resting pHi and NHE activity were also significantly increased by DeHE (0.1-0.3 μM).
    We concluded for the first time that, in the human hearts, DeHE could antagonize triggered arrhythmias induced by cardiotonic agents through a general reduction of the Na(+) and Ca(2+) inward currents, while increase of resting pHi and NHE activity.
    In vivo:
    Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
    Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.[Pubmed: 11226396]
    Dehydroevodiamine has been reported to have anticholinesterase activity and an anti-amnesic effect.
    This study examined the effects of Dehydroevodiamine on scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia in mice, using a step-through passive avoidance test. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), Dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia. In beta-amyloid peptide-(25--35)-induced amnesia, the rank order of anti-amnesic potency in these three administration schedules for Dehydroevodiamine was different from that for physostigmine. Furthermore, Dehydroevodiamine was more potent to improve beta-amyloid peptide-(25--35)-induced amnesia than scopolamine-induced amnesia when administered before the training trial.
    These results suggested that Dehydroevodiamine may have an action other than that of an anticholinesterase and may be a novel and effective ligand for improvement of beta-amyloid type amnesia.
    Dehydroevodiamine Description
    Source: The fruits of Evodia rutaecarpa.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN92288
    CAS No: 24404-50-0
    Price: $338/5mg
    20(21)-Dehydrolucidenic acid A

    Catalog No: CFN90829
    CAS No: 852936-69-7
    Price: $358/5mg

    Catalog No: CFN90720
    CAS No: 59952-97-5
    Price: $318/5mg
    Poricoic acid G

    Catalog No: CFN95056
    CAS No: 415724-84-4
    Price: $318/5mg

    Catalog No: CFN92616
    CAS No: 7727-79-9
    Price: $278/20mg
    3,6'-Disinapoyl sucrose

    Catalog No: CFN90578
    CAS No: 139891-98-8
    Price: $138/20mg

    Catalog No: CFN92341
    CAS No: 105037-88-5
    Price: $318/10mg

    Catalog No: CFN95010
    CAS No: 50816-74-5
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.3179 mL 16.5893 mL 33.1785 mL 66.357 mL 82.9463 mL
    5 mM 0.6636 mL 3.3179 mL 6.6357 mL 13.2714 mL 16.5893 mL
    10 mM 0.3318 mL 1.6589 mL 3.3179 mL 6.6357 mL 8.2946 mL
    50 mM 0.0664 mL 0.3318 mL 0.6636 mL 1.3271 mL 1.6589 mL
    100 mM 0.0332 mL 0.1659 mL 0.3318 mL 0.6636 mL 0.8295 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Cell Research:
    Life Sci. 2006 Jul 10;79(7):695-701.
    Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages.[Pubmed: 16554073 ]
    Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus.
    We investigated the anti-inflammatory properties of Dehydroevodiamine in RAW 264.7 murine macrophages. The results indicated that Dehydroevodiamine inhibited the expression of LPS-induced iNOS and COX-2 proteins and suppressed also their mRNAs from RT-PCR experiment on RAW 264.7 cells. Furthermore, this compound inhibited the level of LPS-stimulated prostaglandin E2 (PGE2) and LPS-induced nuclear factor-kappa B (NF-kappaB).
    Therefore, we suggested that the effect of Dehydroevodiamine-mediated inhibition of the expression LPS-induced iNOS and COX-2 genes is due to under the suppression of NF-kappaB activation in the transcriptional level.